102 related articles for article (PubMed ID: 17240136)
1. Quality assurance in breast cancer: EORTC experiences in the phase III trial on irradiation of the internal mammary nodes.
Musat E; Poortmans P; Van den Bogaert W; Struikmans H; Fourquet A; Bartelink H; Kirkove C; Budach V; Pierart M; Collette L
Eur J Cancer; 2007 Mar; 43(4):718-24. PubMed ID: 17240136
[TBL] [Abstract][Full Text] [Related]
2. Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925).
Matzinger O; Heimsoth I; Poortmans P; Collette L; Struikmans H; Van Den Bogaert W; Fourquet A; Bartelink H; Ataman F; Gulyban A; Pierart M; Van Tienhoven G;
Acta Oncol; 2010; 49(1):24-34. PubMed ID: 20100142
[TBL] [Abstract][Full Text] [Related]
3. Quality assurance in the EORTC randomized trial 22922/10925 investigating the role of irradiation of the internal mammary and medial supraclavicular lymph node chain works.
Poortmans P; Kouloulias V; van Tienhoven G; Collette L; Struikmans H; Venselaar JL; Van den Bogaert W; Davis JB; Lambin P;
Strahlenther Onkol; 2006 Oct; 182(10):576-82. PubMed ID: 17013570
[TBL] [Abstract][Full Text] [Related]
4. [Irradiation of lymph nodes areas in breast cancer].
Hennequin C; Romestaing P; Maylin C
Cancer Radiother; 2008 Nov; 12(6-7):559-64. PubMed ID: 18951822
[TBL] [Abstract][Full Text] [Related]
5. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial.
Poortmans PM; Weltens C; Fortpied C; Kirkove C; Peignaux-Casasnovas K; Budach V; van der Leij F; Vonk E; Weidner N; Rivera S; van Tienhoven G; Fourquet A; Noel G; Valli M; Guckenberger M; Koiter E; Racadot S; Abdah-Bortnyak R; Van Limbergen EF; Engelen A; De Brouwer P; Struikmans H; Bartelink H;
Lancet Oncol; 2020 Dec; 21(12):1602-1610. PubMed ID: 33152277
[TBL] [Abstract][Full Text] [Related]
6. The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain: a quality-assurance report on the dummy run of EORTC Phase III randomized trial 22922/10925 in Stage I--III breast cancer(1).
Poortmans PM; Venselaar JL; Struikmans H; Hurkmans CW; Davis JB; Huyskens D; van Tienhoven G; Vlaun V; Lagendijk JJ; Mijnheer BJ; De Winter KA; Van der Hulst MH; Van den Bogaert WF
Int J Radiat Oncol Biol Phys; 2001 Apr; 49(5):1399-408. PubMed ID: 11286848
[TBL] [Abstract][Full Text] [Related]
7. Economic consequence of local control with radiotherapy: cost analysis of internal mammary and medial supraclavicular lymph node radiotherapy in breast cancer.
Lievens Y; Kesteloot K; van den Bogaert W
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1122-31. PubMed ID: 16253774
[TBL] [Abstract][Full Text] [Related]
8. DEGRO practical guidelines for radiotherapy of breast cancer II. Postmastectomy radiotherapy, irradiation of regional lymphatics, and treatment of locally advanced disease.
Sautter-Bihl ML; Souchon R; Budach W; Sedlmayer F; Feyer P; Harms W; Haase W; Dunst J; Wenz F; Sauer R
Strahlenther Onkol; 2008 Jul; 184(7):347-53. PubMed ID: 19016032
[TBL] [Abstract][Full Text] [Related]
9. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.
Toledano A; Azria D; Garaud P; Fourquet A; Serin D; Bosset JF; Miny-Buffet J; Favre A; Le Floch O; Calais G
J Clin Oncol; 2007 Feb; 25(4):405-10. PubMed ID: 17264336
[TBL] [Abstract][Full Text] [Related]
10. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.
Lale Atahan I; Yildiz F; Ozyigit G; Sari S; Gurkaynak M; Selek U; Hayran M
Acta Oncol; 2008; 47(2):232-8. PubMed ID: 17924207
[TBL] [Abstract][Full Text] [Related]
11. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
Johansen J; Overgaard J; Overgaard M
Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
[TBL] [Abstract][Full Text] [Related]
13. Quality assurance in the EORTC phase III randomised 'boost vs. no boost' trial for breast conserving therapy: comparison of the results of two individual case reviews performed early and late during the accrual period.
Poortmans PM; Ataman F; Davis JB; Bartelink H; Horiot JC; Pierart M; Collette L; Van Tienhoven G
Radiother Oncol; 2005 Sep; 76(3):278-84. PubMed ID: 15919127
[TBL] [Abstract][Full Text] [Related]
14. EORTC 22972-26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost arm.
Baumert BG; Brada M; Bernier J; Kortmann RD; Dehing-Oberije C; Collette L; Davis JB
Radiother Oncol; 2008 Aug; 88(2):163-72. PubMed ID: 18455252
[TBL] [Abstract][Full Text] [Related]
15. Quality assurance of EORTC trial 22922/10925 investigating the role of internal mammary--medial supraclavicular irradiation in stage I-III breast cancer: the individual case review.
Poortmans P; Kouloulias VE; Venselaar JL; Struikmans H; Davis JB; Huyskens D; van Tienhoven G; Hurkmans C; Mijnheer B; Van den Bogaert W
Eur J Cancer; 2003 Sep; 39(14):2035-42. PubMed ID: 12957458
[TBL] [Abstract][Full Text] [Related]
16. Arm and shoulder morbidity in breast cancer patients after breast-conserving therapy versus mastectomy.
Nesvold IL; Dahl AA; Løkkevik E; Marit Mengshoel A; Fosså SD
Acta Oncol; 2008; 47(5):835-42. PubMed ID: 18568481
[TBL] [Abstract][Full Text] [Related]
17. The feasibility of sentinel node biopsy in the previously treated breast.
Koizumi M; Koyama M; Tada K; Nishimura S; Miyagi Y; Makita M; Yoshimoto M; Iwase T; Horii R; Akiyama F; Saga T
Eur J Surg Oncol; 2008 Apr; 34(4):365-8. PubMed ID: 17532172
[TBL] [Abstract][Full Text] [Related]
18. Internal mammary nodal irradiation in conservatively-managed breast cancer patients: is there a benefit?
Obedian E; Haffty BG
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):997-1003. PubMed ID: 10421532
[TBL] [Abstract][Full Text] [Related]
19. Does concurrent radiochemotherapy affect cosmetic results in the adjuvant setting after breast-conserving surgery? Results of the ARCOSEIN multicenter, Phase III study: patients' and doctors' views.
Toledano AH; Bollet MA; Fourquet A; Azria D; Gligorov J; Garaud P; Serin D; Bosset JF; Miny-Buffet J; Favre A; LeFoch O; Calais G
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):66-72. PubMed ID: 17448869
[TBL] [Abstract][Full Text] [Related]
20. A long-term study of radiation therapy in t1-2 node-negative breast cancer patients in relation to the number of axillary nodes examined.
Tai P; Yu E; Sadikov E; Joseph K
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):453-7. PubMed ID: 18947940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
